Form 4: Apellis CSO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold 909 shares of common stock to cover tax obligations related to Restricted Stock Units.

Summary

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, Inc., reported a transaction involving the company's common stock.
• On January 20, 2026, 909 shares of common stock were sold at a price of $19.7929 per share.
• The sale was executed to cover tax withholding obligations associated with Restricted Stock Units that were released on January 16, 2026.
• Following this transaction, Deschatelets beneficially owns 1,157,310 shares of Apellis Pharmaceuticals, Inc. common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine administrative sale for tax purposes following RSU vesting, which is neutral in sentiment. It does not indicate a change in management's view of the company's prospects.

Industry Context

This is a routine insider transaction for tax purposes and does not reflect broader industry trends or competitive positioning. It is a common occurrence when Restricted Stock Units vest for executives in publicly traded companies.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a small, routine administrative transaction by an individual officer for tax purposes.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Pascal Deschatelets, Chief Scientific Officer, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, RSU